目的 探討心通口服液聯(lián)合阿司匹林治療冠心病心絞痛的臨床療效。方法 選取2021年3月—2022年3月北京友誼醫(yī)院收治的116例冠心病心絞痛患者，按隨機(jī)數(shù)字表法將所有患者分為對(duì)照組和治療組，每組各58例。對(duì)照組口服阿司匹林腸溶片，1片/次，1次/d。治療組在對(duì)照組治療基礎(chǔ)上口服心通口服液，10 mL/次，3次/d。兩組療程均為4周。觀察兩組的臨床療效，比較兩組治療前后心絞痛發(fā)作情況、凝血功能指標(biāo)[D-二聚體（D-D）、纖維蛋白原（FIB）、凝血酶原時(shí)間（PT）]和炎癥指標(biāo)[C反應(yīng)蛋白（CRP）、血小板與淋巴細(xì)胞比值（PLR）、中性粒細(xì)胞與淋巴細(xì)胞比值（NLR）等]變化情況。并統(tǒng)計(jì)兩組不良反應(yīng)情況。結(jié)果 治療后，治療組心絞痛、心電圖總有效率分別是94.83%、89.66%，均顯著高于對(duì)照組的82.76%、75.86%（P＜0.05）。治療后，兩組心絞痛發(fā)作次數(shù)、硝酸甘油用量、持續(xù)時(shí)間均顯著降低（P＜0.05）；治療后，治療組病情控制情況優(yōu)于對(duì)照組（P＜0.05）。治療后，兩組血漿D-D、FIB水平均顯著降低，而PT均顯著延長(zhǎng)（P＜0.05）；治療后，治療組凝血功能指標(biāo)改善優(yōu)于對(duì)照組（P＜0.05）。治療后，兩組PLR、NLR、CRP均較同組治療前顯著降低（P＜0.05）；治療后，治療組炎癥相關(guān)指標(biāo)低于對(duì)照組（P＜0.05）。治療后，治療組和對(duì)照組的不良反應(yīng)發(fā)生率分別是8.62%、6.90%，兩組比較差異無(wú)統(tǒng)計(jì)學(xué)意義。結(jié)論 心通口服液聯(lián)合阿司匹林治療冠心病心絞痛整體療效顯著，可顯著改善機(jī)體凝血功能，抑制機(jī)體炎癥狀態(tài)，有效控制心絞痛發(fā)作，值得臨床推廣應(yīng)用。

Objective To explore the clinical efficacy of Xintong Oral Liquid combined with aspirin in treatment of angina pectoris of coronary heart disease. Methods 116 Patients with angina pectoris of coronary heart disease admitted to Beijing Friendship Hospital from March 2021 to March 2022 were selected and divided into control group and treatment group according to random number table method, with 58 patients in each group. Patients in the control group were po administered with Aspirin Enteric-coated Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Xintong Oral Liquid on the basis of the control group, 10 mL/time, three times daily. The treatment course of both groups was 4 weeks. The clinical efficacy of two groups was observed. After treatment, angina pectoris attack, coagulation function index [D-dimer (D-D), fibrinogen (FIB), prothrombin time (PT)] and inflammation index [C-reactive protein (CRP), platelet-lymphocyte ratio (PLR), neutrophil to lymphocyte ratio (NLR)] were compared between two groups before and after treatment. The adverse reactions of the two groups were analyzed. Results After treatment, the total effective rates of angina pectoris and electrocardiogram in treatment group were 94.83% and 89.66%, respectively, which were significantly higher than 82.76% and 75.86% in control group (P < 0.05). After treatment, the frequency of angina pectoris attack, the amount of nitroglycerin and the duration of angina pectoris in both groups were significantly decreased (P < 0.05). After treatment, the condition control of treatment group was better than that of control group (P < 0.05). After treatment, plasma D-D and FIB levels were significantly decreased, but PT was significantly prolonged in both groups (P < 0.05). After treatment, the improvement of coagulation function index in treatment group was better than that in control group (P < 0.05). After treatment, PLR, NLR and CRP in 2 groups were significantly decreased compared with before treatment (P < 0.05). After treatment, the inflammation-related indexes in treatment group were lower than those in control group (P < 0.05). After treatment, the incidence of adverse reactions in the treatment group and the control group was 8.62% and 6.90%, respectively, and there was no statistical significance between the two groups. Conclusion Xintong Oral Liquid combined with aspirin has a significant overall therapeutic effect in treatment of angina pectoris of coronary heart disease, and can significantly improve the coagulation function of the body, inhibit the inflammatory state of the body, and effectively control the attack of angina pectoris, which is worthy of clinical application.

R972

首都醫(yī)科大學(xué)附屬北京友誼醫(yī)院院內(nèi)項(xiàng)目（YY9dkt2017-h16）